Vertex Pharmaceuticals Inc sales and marketing update

Vertex signed a letter of intent with the pan-Canadian Pricing Alliance (pCPA) to enable public reimbursement of Kalydeco ivacaftor to treat cystic fibrosis in patients ages six years and older who have at least one copy of the G551D mutation in the CF transmembrane conductance regulator ( CFTR) gene. Vertex said each participating province or territory must also decide to reimburse Kalydeco through its individual drug program before patients have access. According to the company, there are about 100 patients ages six years and older in Canada with the G551D mutation. ...